Omnacortil 2.5mg (Prednisolone)
Omnacortil 2.5mg is the first drug of choice for most patients with primary Nephrotic Syndrome. Omnacortil 2.5mg is indicated for the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Omnacortil 2.5mg also Indicated to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis.
Omnacortil belongs to a class of drugs known as corticosteroids. A glucocorticoid with the common properties of the corticosteroids.
It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Corticosteroids controls by reducing the body’s immune system response to various diseases or conditions which produce symptoms such as swelling, inflammation, and allergic-type reactions. Omnacortil is a prescription drug which used under the supervision of medical practioners
Omnacortil is the first drug of choice for most patients with primary Nephrotic Syndrome. Omnacortil is indicated for the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Omnacortil also Indicated to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis.
Omnacortil also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rheumatic carditis. Omnacortil also indicated in the treatment of leukaemia’s, lymphomas, thrombocytopenia purpura and autoimmune haemolyticAnemia. Omnacortil also indicated to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
Omnacortil absorbs readily in gastrointestinal tract, peak plasma concentration is 1-2 hr after administration.
Very high protein bounding about >90%.
Omnacortil is mainly metabolised in liver and eliminated in the urine as sulphate and glucuronide
Eliminated from the plasma with a mean. Half-life of the drug is 2-3 hours.
Electrolyte imbalance, Headache, Fragile skin, Decreased libido, Bone degradation, Menstrual cycle alteration, Infection risk increased, Insomnia, Hair growth increased, Muscle disorders, Changes in personality, Menstrual periods absence, Acne, High blood pressure, Redness of skin, Skin scar
Omnacortil may increase the blood glucose levels and decline the symptoms of diabetes. The patients with diabetes should Use with caution. Tablet may decreased the bone density by reduce the absorption of calcium. Tablet is needed with caution in the patients with liver injury and impaired kidney function.
This medicine should be avoided for pregnant women. This tablet is known to excreted via breast milk in little amounts so not advisable for breast feeder. Tablet may reduce the effect of live or vitiate vaccines.
Combination with Amino glutethimide may lead to loss of corticosteroid-induced adrenal suppression. There have been cases resulted in which combination of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see also Potassium depleting agents).
Interaction of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If probably, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. CYP 3A4 inhibitors Ketoconazole has been resulted to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects.
Omnacortil interaction with Cholestyramine may increase the clearance of corticosteroids. Patients on taking Omnacortil interaction with digitalis glycosides may be at increased risk of arrhythmias due to hypokalaemia.
Omnacortil Orally Disintegrating Tablets are contraindicated in patients who are hypersensitive to corticosteroids i.e. prednisolone or any components of this product. Sometime particular of anaphylactoid reactions have appeared in patients getting corticosteroid therapy.
Category C: In studies, Animal reproduction have reveal an adverse reaction on the foetus and there are no sufficient and well-regulated studies in humans, but possible benefits may credential use of the drug needed despite possible risks in pregnant women.
Omnacortil is very improbable to cause adverse reaction in the infant. Discuss your doctor if you are breastfeeding your child and use the medicine as advised
Stored at < 25°C keep in a cool, dry place away from heat and sunlight. Keep Omnacortil reach out of children. Do not keep medicine after expired. Discuss with the pharmacist on how to dispose of Omnacortil which has expired.
Take a missed dose immediately you think about it. If time comes closer to your next dose, skip the missed dose and go back to your normal time. Do not have double doses at the same time. Avoid the change of the dose or stop this drug. Discuss with the doctor.